Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Apr;65(4):404-411.
doi: 10.4103/indianjpsychiatry.indianjpsychiatry_389_22. Epub 2023 Apr 11.

Oral versus long-acting injectable antipsychotic in first episode schizophrenia: A 12 weeks interventional study

Affiliations

Oral versus long-acting injectable antipsychotic in first episode schizophrenia: A 12 weeks interventional study

Ramandeep Kaur et al. Indian J Psychiatry. 2023 Apr.

Abstract

Background: There is underutilization of long-acting injectable (LAI) antipsychotics for first-episode schizophrenia (FES) despite having convenient dosing and treatment retention. LAIs are predominantly used for patients with poor compliance, chronic course, and multiple relapses.

Materials and methods: Seventy-two treatment naïve patients with the first episode of Schizophrenia (DSM-5) were assessed for baseline severity of psychopathology using the positive and negative syndrome scale (PANSS) and quality of life (QOL) using the WHOQOL-BREF scale. Patients were randomized to receive either oral haloperidol or LAI haloperidol for a period of 12 weeks.

Results: Both the groups had a significant reduction in PANSS scores and improvement in QoL over 12 weeks period (P = 0.0001). The LAI group showed greater adherence and significantly better quality of life than the oral group (P = 0.023). The mean numbers of side effects were less in the LAI group at week 2 as compared to the oral group.

Conclusion: LAI haloperidol is similar to oral haloperidol in patients with FES with respect to treatment response and offers benefits in form of a lesser number of side effects during early treatment, overall better adherence rates, and better QOL.

Keywords: Adherence; FES; LAI; antipsychotic; first-episode schizophrenia; quality of life.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest.

Figures

Figure 1
Figure 1
Flow chart

Similar articles

Cited by

References

    1. Zhornitsky S, Stip E. Oral versus long-acting injectable antipsychotics in the treatment of schizophrenia and special populations at risk for treatment non adherence: A systematic review. Schizophr Res Treatment. 2012;2012:407171. - PMC - PubMed
    1. Tandon R, Nasrallah HA, Keshavan MS. Schizophrenia, “just the facts”. Clinical features and conceptualization. Schizophr Res. 2009;110:1–23. - PubMed
    1. De Bont R. Schizophrenia, evolution and the borders of biology: On Huxley et al.'s 1964 paper in Nature. Hist Psychiatry. 2010;21:144–59. - PubMed
    1. Thomas SP, Nandhra HS, Singh SP. Pharmacologic treatment of first-episode schizophrenia: A review of the literature. Prim Care Companion CNS Disord. 2012;14:PCC.11r01198. - PMC - PubMed
    1. Kahn RS, Fleischhacker WW, Boter H, Davidson M, Vergouwe Y, Keet IPM, et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: An open randomised clinical trial. Lancet. 2008;371:1085–97. - PubMed